Global Manufacturing Footprint US Pharma Lab's extensive manufacturing facilities spanning over 500,000 sq. ft. in the US and China provide a robust platform for scaling production and supporting international clients, presenting opportunities for partners seeking reliable global manufacturing solutions.

Recent Acquisition Expansion The recent acquisition by Biofarma Group enhances US Pharma Lab’s resource network and technological capabilities, enabling cross-selling of integrated pharmaceutical and nutraceutical development services across diverse markets.

Technological Infrastructure Leveraging advanced tools like AWS, AutoCAD, and Microsoft 365, US Pharma Lab demonstrates a commitment to modern manufacturing processes, opening doors for collaborations involving digital transformation, automation, and data-driven quality assurance.

Strong Industry Partnerships Collaborations such as the manufacturing agreement with OptiBiotix Health indicate US Pharma Lab's active engagement with innovative brands in health and wellness sectors, creating sales opportunities for co-development and supply chain expansion.

Market Position & Revenue With revenues ranging from 50 to 100 million dollars and a strategic focus on quality and consistency, US Pharma Lab is positioned as a reliable partner for mid-sized global brands seeking high-quality contract manufacturing solutions in nutraceuticals and related sectors.